Ignite Creation Date:
2024-05-06 @ 7:15 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05948462
Status:
WITHDRAWN
Last Update Posted:
2023-12-13
First Post:
2023-06-27
Brief Title:
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive ALK Non-small Cell Lung Cancer NSCLC Who Progressed on Single-agent Lorlatinib
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Organization Data
Organization:
SCRI Development Innovations LLC
Class:
OTHER
Study ID:
LUN 481
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
SCRI Development Innovations LLC
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |